FDA Clarifies When It’s OK to Miss Postmarketing Requirement Milestones

In an effort to improve adherence with postmarketing requirements (PMR), the FDA has laid out the circumstances under which noncompliance with PMRs is justified in a new draft guidance.
Source: Drug Industry Daily